Kahook Malik Y. 4

What Happened
Malik Y. Kahook (identified as President, Chief Medical Officer, Executive Chair) was granted a derivative award of 105,000 shares on February 5, 2026. The award was reported as an "A" (grant/award) at a $0.00 acquisition price (i.e., no cash paid at grant) and is issued under the issuer's 2026 Equity Incentive Plan.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (four days after the grant). This exceeds the typical two-business-day deadline for Section 16 filings and may be a late filing.
• Amount and price: 105,000 shares; acquisition price reported as $0.00 (derivative grant).
• Shares owned after transaction: Not specified in the provided filing.
• Vesting: Per the footnote, 25% vests on the one-year anniversary of the Vesting Commencement Date (Feb 5, 2027), then 1/48th of the shares vests monthly thereafter (standard four-year vesting schedule), conditional on continuing as a Service Provider.
• Instrument: Described as a derivative award under the 2026 Equity Incentive Plan (footnote refers to an option).

Context

• This was a compensation grant (award of derivative securities), not an open-market purchase or sale; such grants are routine executive compensation and do not necessarily signal near-term buying or selling intent.
• The award vests over time and is contingent on continued service; shares are not immediately available for sale unless and until they vest and, if options, are exercised.